Funded Grants

Back to results

Synergistic combination of IAP antagonism and immunotherapy to treat brain cancers

Project Overview

Brain cancers can be exceptionally challenging to treat, and new therapies are needed. Cancer cells can resist treatment in part through proteins that protect cells from dying called IAPs. Dr Robert Korneluk has found that combining IAP-blocking drugs with immunotherapy can kill cancer cells very effectively. Dr Korneluk will now define the most effective cocktail of IAP blocking drugs and immunotherapies (e.g. cancer fighting viruses and other immune system stimulants) in mice with an aggressive form of brain cancer. This will lay the foundation for clinical trials to test this new approach to brain cancer treatment.

Principal Investigator

Robert Korneluk , University of Ottawa/CHEO

Partners and Donors

Canadian Cancer Society

Project Ongoing

Synergistic combination of IAP antagonism and immunotherapy to treat brain cancers

  • Program Type

    Team grants

  • Area of research

    Cancer

  • Disease Area

    Brain Cancer

  • Competition

    Canadian Cancer Society Impact Grants

  • Province

    Ontario

  • Start Date

    2016

  • Total Grant Amount

    $1,200,000

  • Health Canada Contribution

    $600,000